STAT+: A Huntington’s researcher on the UniQure-FDA fray

Summary: In today's health news, Johnson & Johnson just got a new pill approved to treat psoriasis, and some experts think Eli Lilly's stock costs too much. But the big story is about an experimental treatment for Huntington's disease. Last year, a biotech company named UniQure said their new gene therapy slowed down this untreatable condition by 75%. Dr. Ed Wild, a top researcher from University College London, even called it the result they had been waiting for. However, things have changed since then, and now the researcher is having to carefully navigate new drama between UniQure and the FDA.

For more details, see statnews at statnews.com/2026/03/18/huntingtons-uniqure-fda-jnj-psoriasis-icotyde-readout-newsletter/?utm_campaign=rss (opens in new tab)